Proteinase-activated receptors and the pathophysiology of pulmonary fibrosis

被引:7
|
作者
Chambers, RC [1 ]
机构
[1] UCL, Ctr Resp Res, London WC1E 6JJ, England
关键词
PARs; pulmonary fibrosis; bleomycin;
D O I
10.1002/ddr.10317
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Interest in the role of proteinase-activated receptors (PARs) in the pathogenesis of fibrotic lung disease was fuelled by two central observations: first, the recognition that the coagulation cascade is activated in a number of these disorders; and second, the long-standing observation that thrombin, a principal regulator of coagulation, is a potent mitogen for fibroblasts, the key cell type responsible for the production of interstitial collagens in the fibrotic lung. This article will briefly review this evidence and focus on recent studies suggesting an important role for PAR(1)-mediated cellular responses in the pathophysiology of lung fibrosis. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [41] Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells
    Hansen, KK
    Saifeddine, M
    Hollenberg, MD
    IMMUNOLOGY, 2004, 112 (02) : 183 - 190
  • [42] Dihydroartemisinin supresses inflammation and fibrosis in bleomycine-induced pulmonary fibrosis in rats
    Yang, Dongxia
    Yuan, Wendan
    Lv, Changjun
    Li, Naie
    Liu, Tongshen
    Wang, Liang
    Sun, Yufei
    Qiu, Xueshan
    Fu, Qiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 1270 - 1281
  • [43] Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis
    Mou, Fanghong
    Mou, Canglang
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [44] Proteinase- activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways
    El-Daly, Mahmoud
    Saifeddine, Mahmoud
    Mihara, Koichiro
    Ramachandran, Rithwik
    Triggle, Christopher R.
    Hollenberg, Morley D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (09) : 2413 - 2425
  • [45] Considerations for therapeutic intervention models of pulmonary fibrosis
    JA Wilder
    M Doyle-Eisele
    KM Gott
    Y Shi
    R Guilmette
    A Gigliotti
    J McDonald
    IO Rosas
    Journal of Inflammation, 10 (Suppl 1)
  • [46] From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump
    Selman, Moises
    Pardo, Annie
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2021, 321 (03) : L600 - L607
  • [47] The efficacy of pirfenidone in a sheep model of pulmonary fibrosis
    Dewage, Sasika N., V
    Organ, Louise
    Koumoundouros, Emmanuel
    Derseh, Habtamu B.
    Perera, Kopiyawaththage U. E.
    Samuel, Chrishan S.
    Stent, Andrew W.
    Snibson, Ken J.
    EXPERIMENTAL LUNG RESEARCH, 2019, 45 (9-10) : 310 - 322
  • [48] Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
    Skurikhin, Evgenii
    Nebolsin, Vladimir
    Widera, Darius
    Ermakova, Natalia
    Pershina, Olga
    Pakhomova, Angelina
    Krupin, Vyacheslav
    Pan, Edgar
    Zhukova, Mariia
    Novikov, Fedor
    Sandrikina, Lubov
    Morozov, Sergey
    Kubatiev, Aslan
    Dygai, Alexander
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) : 1 - 19
  • [49] Imbalance of dendritic cell function in pulmonary fibrosis
    Yuan, Yuan
    CYTOKINE, 2024, 181
  • [50] Role of Prostaglandin (PG) and Peroxisome Proliferator-Activated Gamma (PPAR gamma) in Pulmonary Fibrosis
    Hayashi, Izumi
    Endo, Hirahito
    Katagiri, Masato
    Kitasato, Hidero
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2009, 5 (01) : 3 - 5